Trial Profile
Role of 123I-Ioflupane in SPECT imaging as a prognostic marker of dyskinesias
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2017
Price :
$35
*
At a glance
- Drugs Ioflupane 123I (Primary)
- Indications Parkinson's disease
- Focus Diagnostic use
- 27 Jul 2017 New trial record
- 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology